Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 32 of 151

  1. CADPT17A12201

    Novartis Pharmaceuticals

    Moderate to severe atopic dermatitis

    phase 2 small molecule active

    1 trial

  2. CAIV-T

    MedImmune

    Influenza

    phase 2 mab completed

    1 trial

  3. CAM2038

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 2 small molecule completed

    1 trial

  4. CAMN107AIT15

    Novartis Pharmaceuticals

    Chronic myeloid leukemia

    phase 2 small molecule active

    1 trial

  5. CAMO959A12103

    Novartis Pharmaceuticals

    PSMA-positive mCRPC with prior exposure to at least one prior ARPI

    phase 2 small molecule active

    1 trial

  6. CAN-201 NDG

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 2 other active

    1 trial

  7. CAN-2409

    Candel Therapeutics

    Malignant Glioma

    phase 2 mab completed

    1 trial

  8. CANNABIDIOL, DRONABINOL

    Disc Medicine

    Patients with untreatable hepatocellulare carcinoma

    phase 2 small molecule active

    1 trial

  9. CAP-1002

    CAPRICOR THERAPEUTICS, INC.

    Muscular Dystrophies

    phase 2 mab completed

    1 trial

  10. CAP-1002

    CAPRICOR THERAPEUTICS, INC.

    Covid19

    phase 2 mab completed

    1 trial

  11. CAP-1002 Allogeneic Cardiosphere-Derived Cells

    CAPRICOR THERAPEUTICS, INC.

    Myocardial Infarction

    phase 2 mab terminated

    1 trial

  12. CAPECITABINE , OXALIPLATIN

    Disc Medicine

    Patients with early-stage rectal cancer (defined as early rectal cancer cT1-3abN0M0 or early-intermediate rectal cancer cT1-3abN1(≤3 nodes ≤8mm)M0

    phase 2 small molecule active

    1 trial

  13. CAPECITABINE , VALPROIC ACID

    Fondazione Telethon ETS

    low- risk rectal cancel

    phase 2 small molecule active

    1 trial

  14. CAPECITABINE for Colon cancer

    Fondazione Telethon ETS

    Colon cancer

    phase 2 small molecule active

    1 trial

  15. CAPLAND

    Fondazione Telethon ETS

    Advanced or metastatic untreated EGFR mutation positive NSCLC

    phase 2 small molecule active

    1 trial

  16. CAPTURE

    Fondazione Telethon ETS

    Patients with advanced oncologic disease receiving active treatment with WHO level II or III opioids and adjuvants therapies

    phase 2 small molecule active

    1 trial

  17. CAR T-cell therapy

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia With Failed Remission

    phase 2 mab active

    1 trial

  18. CAR-BCMA T Cells

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 2 mab active

    1 trial

  19. CAR-T

    The First People's Hospital of Lianyungang

    Leukemia, Lymphocytic, Chronic, B-Cell

    phase 2 mab active

    1 trial

  20. CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance

    Daihong Liu

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

    phase 2 small molecule active

    1 trial

  21. CAR-T Cells

    The First People's Hospital of Lianyungang

    Lung Neoplasm Malignant

    phase 2 mab active

    1 trial

  22. CAR-T treatment

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 2 mab active

    1 trial

  23. CARBOCAINE 20 mg/ml, solution injectable

    Pari Pharma GmbH

    Ischemic stroke

    phase 2 small molecule active

    1 trial

  24. CART infusion

    Hospital Authority, Hong Kong

    B-cell Lymphoma Refractory

    phase 2 other active

    1 trial

  25. CART19-BE-02

    The George Institute

    Acute lymphoid leukemia

    phase 2 small molecule active

    1 trial

  26. CARTBCMA-HCB-01

    The George Institute

    Multiple Myeloma

    phase 2 other active

    1 trial

  27. CAT-01

    The George Institute

    Cervical carcinoma

    phase 2 other active

    1 trial

  28. CAT-PSY

    Fondazione Telethon ETS

    Substance-Induced Psychosis

    phase 2 small molecule active

    1 trial

  29. CB-01-33/01

    Cosmo Technologies Ltd

    bile acid diarrhoea (BAD)

    phase 2 small molecule active

    1 trial

  30. CB-01-35/01

    Cosmo Technologies Ltd

    patients with mild to moderate left-sided ulcerative colitis

    phase 2 small molecule active

    1 trial

  31. CBD 400 mg

    Jazz Pharmaceuticals Ireland Limited

    Opiate Addiction

    phase 2 small molecule completed

    1 trial

  32. CBD Oral Solution

    Jazz Pharmaceuticals Ireland Limited

    Fragile X Syndrome

    phase 2 small molecule active

    1 trial

  33. CBD Oral Solution (eCBD system Target)

    Jazz Pharmaceuticals Ireland Limited

    Fragile X Syndrome

    phase 2 small molecule active

    1 trial

  34. CBD-ESPRIT

    The George Institute

    Remitted early phase schizophrenia

    phase 2 small molecule active

    1 trial

  35. CBP-201

    S.L

    Moderate-to-severe Atopic Dermatitis

    phase 2 small molecule completed

    2 trials

  36. CBP-201

    S.L

    Chronic Rhinosinusitis With Nasal Polyps

    phase 2 small molecule terminated

    1 trial

  37. CBP-201

    S.L

    Moderate to Severe Persistent Asthma

    phase 2 small molecule completed

    1 trial

  38. CBYL719F12201

    Novartis Pharmaceuticals

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  39. CBYL719F12202

    Novartis Pharmaceuticals

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  40. CBYL719F12401

    Novartis Pharmaceuticals

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  41. CBYL719X2402

    Novartis Pharmaceuticals

    Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer

    phase 2 small molecule active

    1 trial

  42. CC-220-MM-001

    Celgene Europe Limited

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  43. CC-486-NSCL-001

    Celgene Europe Limited

    Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  44. CC-92480-MM-001

    Celgene Europe Limited

    Relapsed and refractory multiple myeloma (RRMM)

    phase 2 small molecule active

    1 trial

  45. CC-92480-MM-002

    Celgene Europe Limited

    Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM (NDMM)

    phase 2 small molecule active

    1 trial

  46. CC-99282-NHL-001

    Celgene Europe Limited

    Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma

    phase 2 small molecule active

    1 trial

  47. CCFZ533H12201BC

    Novartis Pharmaceuticals

    Moderate to severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  48. CCM-RNT-202402

    Kyverna Therapeutics

    ANCA-IgG-positive ANCA Associated Vasculitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.